Bonus BioGroup : Company Presentation, July 2023

Bonus Biogroup

Company Presentation, July 2023

All information herein is proprietary of Bonus Biogroup Ltd.

Disclaimer and Forward-Looking Statement

This presentation, both written and oral, includes statements that are or may be deemed, ''forward-looking statements'' within the meaning of applicable securities laws. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these terms.

For example, when we discuss the addressable market sizes and growth potential of BonoFill and MesenCure, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results, expressed or implied by such forward-looking statements, could differ materially from Bonus BioGroup's current beliefs, forecasts, and estimates. Factors that could cause or contribute to such differences include, but are not limited to risks and uncertainties associated with natural disasters and public health crises, such as the coronavirus disease (COVID) pandemic; the impact of global economic conditions; regulatory developments; our financing needs; research and development challenges; the demand and acceptance of our products and the other risk factors set forth in Bonus BioGroup's latest annual report and other filings with the Israeli Securities Authority ("ISA"). Any forward- looking statements that we make in this presentation, both written and oral, speak only as of the date of such statement, and, except as required by applicable law, we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation.

This presentation, both written and oral, is not intended to provide you with a complete summary of Bonus BioGroup's business or financial results. For further information about us, you should read our reports and filings with the ISA. Our ISA filings are available at http://www.magna.isa.gov.il and http://maya.tase.co.il.

This presentation, both written and oral, shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale by Bonus BioGroup of any securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

2

Bonus Biogroup is an advanced clinical-stage biotechnology company developing 'next-generation' therapies for a variety of indications in the regenerative medicine field.

Our mission is to develop and deliver effective, safe, and affordable tissue engineering and cell therapy products to address severe diseases and conditions.

Our key assets in advanced clinical trials include:

BonoFill™ is a live human bone graft for treating bone deficiencies based on the patient's own cells, which are grown outside their body.

MesenCure™ is a cell therapy drug product consisting of viable, enhanced mesenchymal cells. It is designed to treat inflammation and tissue damage, including pneumonia and respiratory distress.

Our Vision:

Empower millions of patients to live healthier and longer lives through scientific leadership and excellence, technological innovation, and patient-centric development.

3

Bonus Biogroup stands at the forefront of the industry as a pioneer in regenerative medicine, harnessing our unparalleled knowledge and expertise to develop a unique technological platform that revolutionizes cell therapy and tissue engineering.

By leveraging our deep understanding of the power and challenges of cellular therapeutics, we ensure cost-effectiveness, safety, and quality in our products. This leads to clinical success and enhances our prominent role in the biotech industry.

Dr. Shai Meretzki,

Bonus Biogroup's Founder & CEO

4

BonoFill™

Injectable live human

bone graft

Expands bone grafting availability

Facilitates rapid return to normal functions and about 50% shorter hospitalization and recovery times

Reduces surgery time by 70%

Provides more treatment options

for complicated patients

Reduces hospitalization and

surgery costs by >50%

Reduces the need for revision surgeries

Our products bring value to

Patients

Hospitals

Payers

MesenCure™

Cell therapy for inflammation

and tissue damage

Reduces mortality by 68%

Shortens the duration of

hospitalization by 9 to 10 days

Relieves ICU burden

Provides more treatment options for severe patients

Reduces hospitalization and healthcare costs by ~40%

5	According to an analysis by McKinsey & Company